Kymera Therapeutics Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Kymera Therapeutics Inc had 144.09M in cash and cash equivalents.

Kymera Therapeutics Inc reported 163.15M in total liabilities as of the latest reported quarter, including 83.21M in current liabilities and 79.94M in non-current liabilities.

As of the latest reported quarter, Kymera Therapeutics Inc's total assets were 1.74B, consisting of 871.21M in current assets and 871.60M in non-current assets.

Kymera Therapeutics Inc reported 1.58B in total shareholders' equity as of the latest reported quarter.